Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (NASDAQ:OCS) reported a notification of transactions by a person discharging managerial responsibilities. The notice concerns the vesting and settlement of RSUs previously granted to a company director on May 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – OCS

-36.09% 2.6x vol

41 alerts

-36.09% News Effect

-64.0% Trough in 2 hr 15 min

-$948M Valuation Impact

$1.68B Market Cap

2.6x Rel. Volume

On the day this news was published, OCS declined 36.09%, reflecting a significant negative market reaction. Argus tracked a trough of -64.0% from its starting point during tracking. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $948M from the company's valuation, bringing the market cap to $1.68B at that time. Trading volume was elevated at 2.6x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

What This Means

The stock dropped -36.1% in the session following this news. A negative reaction despite this routin...

Analysis

The stock dropped -36.1% in the session following this news. A negative reaction despite this routine RSU vesting disclosure would resemble past pullbacks after governance and compensation news, such as prior RSU notifications. The underlying filing reports previously granted equity settling to a director, rather than new financing. With an existing Form F-3 covering 494,259 warrant-linked shares, some investors may remain focused on longer-term dilution and capital structure, which could weigh on sentiment during sharp declines.

Historical Context

5 past events · Latest: May 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 15	RSU transactions	Neutral	-7.3%	Disclosure of RSU vesting, settlements, and equity grants to directors.
May 14	AGM results	Neutral	+0.2%	Shareholders approved AGM items, including board election and capital measures.
May 11	Q1 results & update	Neutral	-6.9%	Q1 2026 results, late-stage OCS-01 progress, and cash runway guidance.
May 07	FDA SPA granted	Positive	+5.1%	FDA Special Protocol Assessment for PIONEER-1 registrational Privosegtor trial.
May 05	DME study data	Neutral	-1.8%	Presentation of DME AWARE Delphi findings and timing for DIAMOND topline data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News tied to governance, RSU awards, and financial updates has seen mixed reactions, while the FDA SPA for Privosegtor aligned with a notable positive move.

Recent Company History

Over recent months, Oculis reported several milestones. A May 7 FDA Special Protocol Assessment for PIONEER-1 in optic neuritis coincided with a 5.1% gain, contrasting with declines after Q1 2026 results and prior RSU-related disclosures. The 2026 AGM approved all items, including capital measures, while presentations on DME unmet needs and expectations for DIAMOND Phase 3 results underlined the pipeline focus. Today’s RSU vesting notification fits the pattern of routine governance news.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59 · Short Interest: 1.22%

Shelf Active

Short Interest

1.22% of shares outstanding

as of 2026-05-29 Days to cover: 1

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 dated 2025-11-10 registers the resale of up to 494,259 ordinary shares issuable under a warrant. Oculis is not selling shares in this prospectus and would only receive up to $6,877,246.59 if the warrant is fully exercised for cash.

Key Terms

RSUs

1 terms

RSUs financial

"relates to the vesting and settlement of RSUs previously granted to a director"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Arshad Khanani - 29 May 2026 RSU vest

FAQ

What managerial transaction did Oculis (OCS) report on May 29, 2026?

Oculis reported the vesting and settlement of restricted stock units (RSUs) previously granted to one of its directors. According to Oculis, this transaction involved RSUs held by director Arshad Khanani and was formally disclosed in a managers’ transaction notification.

Who is the director involved in the May 29, 2026 RSU vesting at Oculis (OCS)?

The RSU vesting and settlement notification concerns Oculis director Arshad Khanani. According to Oculis, the attached managers’ transaction notice documents the RSUs previously granted to him and their vesting and settlement as of May 29, 2026.

What type of equity award was involved in the May 29, 2026 Oculis (OCS) director transaction?

The disclosed director transaction involved restricted stock units (RSUs). According to Oculis, the attached notification relates specifically to the vesting and settlement of RSUs that had been granted earlier to director Arshad Khanani under the company’s equity compensation arrangements.

Why did Oculis (OCS) publish a managers’ transaction notification on May 29, 2026?

Oculis published the notification to disclose a reportable transaction by a person discharging managerial responsibilities. According to Oculis, the filing records the vesting and settlement of previously granted RSUs for director Arshad Khanani, consistent with transparency and regulatory disclosure requirements.

Does the May 29, 2026 Oculis (OCS) RSU vesting notice mention any change in director roles?

The notice only references the vesting and settlement of RSUs granted to a director. According to Oculis, the communication identifies director Arshad Khanani in connection with the managers’ transaction, without indicating any change in his role or responsibilities.